Physician profile
Roger D Wu
NPI 1801088596
$3,294.80
in general payments reported to CMS, 2019-2025
21 companies · $1,764 in 2025
The $1,764 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $176 · 2021: $213 · 2023: $69.03 · 2024: $902 · 2025: $1,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,734.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $887.41 | 2019-2025 | Linzess, Creon, Viberzi |
| Janssen Biotech, INC. | $525.13 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $362.79 | 2019-2025 | |
| Ardelyx, INC. | $230.31 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $209.94 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Madrigal Pharmaceuticals | $164.29 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $143.96 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.68 | 2019-2025 | Xifaxan, Plenvu |
| Regeneron Healthcare Solutions, INC. | $133.11 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $98.95 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $68.02 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $65.42 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $51.11 | 2025 | Iqirvo |
| Genzyme Corporation | $48.11 | 2025 | |
| Celgene Corporation | $31.60 | 2023-2024 | Zeposia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $30.81 | 2019-2020 | |
| Amgen INC. | $29.67 | 2025 | |
| Evoke Pharma, INC. | $22.32 | 2021 | |
| Ferring Pharmaceuticals INC. | $19.65 | 2019 | |
| Capsovision, INC. | $17.02 | 2024 | Capsocam Plus |
| Intercept Pharmaceuticals, INC. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.